Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand
Company

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GlaxoSmithKline Plc (GSK; NYSE: GSK) reported Q3 2026 revenues of GBP 8.89 billion (USD 11.91 billion), up 5% at constant exchange rates (CER), driven by double-digit growth in specialty medicines,…

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study
CompanyDrug

Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study

Junshi Biosciences' Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
CompanyDrug

Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma

Aosaikang's Limertinib Approved for EGFR T790M-Mutated NSCLC
CompanyDrug

Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
CompanyDrug

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer

Telix Pharmaceuticals' TLX591-CDx Approved in Europe via Decentralized Procedure
CompanyDrug

Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure

Impact Therapeutics' Senaparib Cleared by NMPA for Ovarian Cancer Therapy
CompanyDrug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Asieris' USP1 Inhibitor APL-2302 Cleared for Clinical Trials
CompanyDrug

Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials

Hengrui's HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
CompanyDrug

Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials

Show More